Cefotiam

Cefotiam

Clinical data
Trade names	Pansporin
AHFS/Drugs.com	International Drug Names
Routes of administration	Intravenous, intramuscular
ATC code	J01DC07 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	60% (intramuscular)
Protein binding	40%
Metabolism	Nil
Elimination half-life	Approximately 1 hour
Excretion	Renal
Identifiers
IUPAC name (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)acetyl] amino}-3-{[1-(2-dimethylaminoethyl)tetrazol-5-yl] sulfanylmethyl}-8-oxo-5-thia-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylic acid
CAS Number	61622-34-2
PubChem CID	43708
DrugBank	DB00229 Y
ChemSpider	39831 Y
UNII	91W6Z2N718
KEGG	D07648 Y
ChEBI	CHEBI:355510 Y
ChEMBL	ChEMBL1296 Y
CompTox Dashboard (EPA)	DTXSID6022763
ECHA InfoCard	100.205.922
Chemical and physical data
Formula	C18H23N9O4S3
Molar mass	525.631 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
InChI InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1 Y Key:QYQDKDWGWDOFFU-IUODEOHRSA-N Y
(verify)

Cefotiam is a parenteral second-generation cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. As a beta-lactam, its bactericidal activity results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins.

In clinical use, high concentrations of cefotiam are observed in several tissues (kidney, heart, ear, prostate and genital tract) as well as in fluids and secretions (bile, ascitic fluid).

Cefotiam was launched as Pansporin in February 1981 by Takeda Pharmaceutical of Japan and has been available as a generic since February 1993.

Mechanism of action

Cefotiam inhibits final cross-linking stage of peptidoglycan production thus inhibiting bacterial cell wall synthesis. It has similar or less activity against Gram positive staphylococci and streptococci, but is resistant to some beta-lactamases produced by Gram negative bacteria. It is more active against many of the Enterobacteriaceae including Enterobacter, E. coli, Klebsiella, Salmonella and indole-positive Proteus species.

Indications

Prophylaxis for surgical infection, postoperative infections, bacterial septicaemia, bone and joint infections, cholangitis, cholecystitis, peritonitis, prostatitis, pyelonephritis, respiratory tract infections, skin and soft tissue infections, cystitis, urethritis and infections caused by susceptible organisms.

It does not have activity against Pseudomonas aeruginosa.

Dosage

Adult: Up to 6 grams daily via intravenous or intramuscular route in divided doses according to severity of infection.

In patients with Renal impairment a dose reduction may be needed.

Adverse effects

Nausea, vomiting, diarrhoea, hypersensitivity reactions, nephrotoxicity, convulsions, CNS toxicity, hepatic dysfunction, haematologic disorders, pain at injection site, thrombophloebitis, Pseudomembranous colitis, superinfection with prolonged use.

See also

• Cephalosporin

External links

• Müller R, Böttger C, Wichmann G (2003). "Suitability of cefotiam and cefuroxime axetil for the perioperative short-term prophylaxis in tonsillectomy patients". Arzneimittelforschung. 53 (2): 126–32. PMID 12642969.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Kolben M, Mandoki E, Ulm K, Freitag K (2001). "Randomized trial of cefotiam prophylaxis in the prevention of postoperative infectious morbidity after elective cesarean section". Eur J Clin Microbiol Infect Dis. 20 (1): 40–2. doi:10.1007/s100960000365. PMID 11245321.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Shimizu S, Chen K, Miyakawa S (1996). "Cefotiam-induced contact urticaria syndrome: an occupational condition in Japanese nurses". Dermatology. 192 (2): 174–6. doi:10.1159/000246352. PMID 8829507.{{cite journal}}: CS1 maint: multiple names: authors list (link)